Question

Is stem cell therapy for Liver Cirrhosis FDA-approved?

The FDA has not approved a stem-cell therapy as a licensed treatment for cirrhosis. Several MSC-based investigational new drugs (INDs) are registered with the NIH, but none has progressed to FDA approval. The EMA likewise has not granted a marketed cirrhosis-specific stem-cell product. Liver transplantation remains the only FDA-approved definitive treatment for decompensated cirrhosis. Patients should distinguish investigational MSC programmes from unproven direct-to-consumer stem-cell marketing, which abounds in cirrhosis given the severity of disease and transplant scarcity.

How stem cells are studied for Liver Cirrhosis

Liver cirrhosis represents end-stage fibrotic liver disease, characterised by irreversible scar tissue replacing functional hepatocytes, portal hypertension, and loss of synthetic function. Stem-cell investigations focus on whether placental mesenchymal stem cells can reduce hepatic fibrosis, promote hepatocyte regeneration, and modulate the immunological and inflammatory drivers of progression. MSCs secrete hepatoprotective factors and anti-fibrotic cytokines (TGF-β antagonists, HGF, FGF) that may arrest stellate-cell activation and collagen deposition. With 89 registered trials — the largest cohort among studied conditions — and 7 currently recruiting, the biological rationale targets the fibrotic cascade rather than curative reversal of established cirrhosis. Early clinical data suggest potential for slowing decompensation, improving synthetic function markers, and delaying transplantation.

Am I a candidate? → · Liver Cirrhosis: full overview → · Liver Cirrhosis cost → · Cost →

Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.

Terapie celulară de nivel european, fără prețuri europene.

Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.

Evaluare medicală gratuită